With a variety of oil stocks reporting full-year 2013 earnings, unconventional assets are the gifts that keep on giving for the oil service trio of Halliburton (HAL), Baker Hughes (BHI) and Schlumberger (SLB).
Hot Cheapest Companies To Watch In Right Now: Chevron Corp (CHV)
Chevron Corporation (Chevron), incorporated on January 27, 1926, manages its investments in subsidiaries and affiliates and provides administrative, financial, management and technology support to the United States and international subsidiaries that engage in fully integrated petroleum operations, chemicals operations, mining activities, power generation and energy services. Upstream operations consist primarily of exploring for, developing and producing crude oil and natural gas; processing, liquefaction, transportation and regasification associated with liquefied natural gas; transporting crude oil by international oil export pipelines; transporting, storage and marketing of natural gas, and a gas-to-liquids project. Downstream operations consist primarily of refining crude oil into petroleum products; marketing of crude oil and refined products; transporting crude oil and refined products by pipeline, marine vessel, motor equipment and rail car, and manufacturing and marketing of commodity petrochemicals, plastics for industrial uses and fuel and lubricant additives.
Upstream
At December 31, 2012, Chevron owned or had under lease or similar agreements undeveloped and developed crude oil and natural gas properties worldwide. Upstream activities in the United States are concentrated in California, the Gulf of Mexico, Colorado, Louisiana, Michigan, New Mexico, Ohio, Oklahoma, Pennsylvania, Texas, West Virginia and Wyoming. During the year ended December 31, 2012, average net oil-equivalent production in the United States was 655,000 barrels per day. In 2012, net daily production averaged 163,000 barrels of crude oil, 70 million cubic feet of natural gas and 4,000 barrels of natural gas liquids (NGLs). During 2012, net daily production for the Company�� combined interests in the Gulf of Mexico shelf and deepwater areas, and the onshore fields in the region, were 153,000 barrels of crude oil, 395 million cubic feet of natural gas and 16,000 barrels of NGL.
The! Company was engaged in various exploration and development activities in the deepwater Gulf of Mexico during 2012. As of December 31, 2012, it had a 50% working interest in Jack and a 51% working interest in St. Malo Field. During 2013, the Company had 42.9% non-operated working interest in the Tubular Bells Field; 20.3% non-operated working interest in the Caesar and Tonga area, and 15.6% non-operated working interest in the Mad Dog II Project. The Company activities in the mid-continental United States include operated and non-operated interests in properties primarily in Colorado, New Mexico, Oklahoma, Texas and Wyoming. The Company holds leases in the Marcellus Shale and Utica Shale, primarily located in southwestern Pennsylvania, Ohio, and West Virginia, and in the Antrim Shale in Michigan. Other Americas is consistd of Argentina, Brazil, Canada, Colombia, Suriname, Trinidad and Tobago, and Venezuela. Net oil-equivalent production from these countries averaged 230,000 barrels per day during 2012, including the Company�� share of synthetic oil production.
Chevron�� interests in oil sands projects and shale acreage in Alberta, shale acreage and an LNG project in British Columbia, exploration, development and production projects offshore in the Atlantic region, and exploration and discovered resource interests in the Beaufort Sea region of the Northwest Territories. Average net oil-equivalent production during 2012, was 69,000 barrels per day, consisted of 25,000 barrels of crude oil, four million cubic feet of natural gas and 43,000 barrels of synthetic oil from oil sands. During 2012, the Company held a 20% non-operated working interest in the Athabasca Oil Sands Project (AOSP). In February 2013, Chevron acquired a 50%-owned and operated interest in the Kitimat LNG project and proposed Pacific Trail Pipeline, and a 50% non-operated working interest in 644,000 total acres in the Horn River and Liard shale gas basins in British Colombia; 26.9% non-operated working interest in the Hib! ernia Fie! ld and a 23.6 non-operated working interest in the unitized Hibernia Southern Extension (HSE) offshore Atlantic Canada, and 26.6% non-operated working interest in the heavy-oil Hebron Field, also offshore Atlantic Canada.
In December 2012, Chevron relinquished its 29.2% non-operated working interest in Exploration License 2007/26, which includes Block 4 offshore West Greenland. The Company holds operated interests in four concessions in the Neuquen Basin. Working interests range from 18.8% to 100%. In 2012, the net oil-equivalent production averaged 22,000 barrels per day, consisted of 21,000 barrels of crude oil and four million cubic feet of natural gas. During 2012, two exploratory wells targeting shale gas and tight oil resources were drilled in the Vaca Muerta formation in the El Trapial concession. Chevron holds working interests in three deepwater fields in the Campos Basin: Frade (51.7%-owned and operated), Papa-Terra and Maromba (37.5% and 30% non-operated working interests, respectively). Net oil-equivalent production in 2012 averaged 6,000 barrels per day, consisted of 6,000 barrels of crude oil and two million cubic feet of natural gas.
In Africa, the Company is engaged in upstream activities in Angola, Chad, Democratic Republic of the Congo, Liberia, Morocco, Nigeria, Republic of the Congo, Sierra Leone and South Africa. Net oil-equivalent production in Africa averaged 451,000 barrels per day during 2012. In Asia, the Company is engaged in upstream activities in Azerbaijan, Bangladesh, Cambodia, China, Indonesia, Kazakhstan, the Kurdistan Region of Iraq, Myanmar, the Partitioned Zone located between Saudi Arabia and Kuwait, the Philippines, Russia, Thailand, and Vietnam. During 2012, net oil-equivalent production averaged 1,061,000 barrels per day. In Australia, the Company�� upstream efforts are concentrated off the northwest coast. During 2012, the average net oil-equivalent production from Australia was 99,000 barrels per day. In Europe, the Company is engag! ed in ups! tream activities in Bulgaria, Denmark, Lithuania, the Netherlands, Norway, Poland, Romania, Ukraine and the United Kingdom. Net oil-equivalent production in Europe averaged 114,000 barrels per day during 2012.
Downstream
The Company markets petroleum products under the principal brands of Chevron, Texaco and Caltex worldwide. In the United States, the Company markets under the Chevron and Texaco brands. During 2012, the Company supplied directly or through retailers and marketers approximately 8,060 Chevron- and Texaco-branded motor vehicle service stations, primarily in the southern and western states. Approximately 470 of these outlets are company-owned or -leased stations. Outside the United States, the Company supplied directly or through retailers and marketers approximately 8,700 branded service stations, including affiliates. In British Columbia, Canada, the Company markets under the Chevron brand. The Company markets in Latin America and the Caribbean using the Texaco brand. In the Asia-Pacific region, southern Africa, Egypt and Pakistan, the Company uses the Caltex brand. The Company also operates through affiliates under various brand names. In South Korea, the Company operates through its 50%-owned affiliate, GS Caltex, and in Australia through its 50%-owned affiliate, Caltex Australia Limited.
The Company owns a 50% interest in its Chevron Phillips Chemical Company LLC (CPChem) affiliate. During 2012, CPChem owned or had joint-venture interests in 36 manufacturing facilities and two research development centers worldwide. The Company�� Oronite brand lubricant and fuel additives business is a developer, manufacturer and marketer of performance additives for lubricating oils and fuels. The Company owns and operates facilities in Brazil, France, Japan, the Netherlands, Singapore and the United States and has interests in facilities in India and Mexico. Oronite lubricant additives are blended into refined base oil to produce finished lubricant packages us! ed primar! ily in engine applications, such as passenger car, heavy-duty diesel, marine, locomotive and motorcycle engines.
Transportation
The Company owns and operates a network of crude oil, refined product, chemical, natural gas liquid and natural gas pipelines and other infrastructure assets in the United States. The Company also has direct and indirect interests in other the United States and international pipelines. All tankers in the Company�� controlled seagoing fleet were utilized during 2012. During 2012, the Company had 51 deep-sea vessels chartered on a voyage basis, or for a period of less than one year. The Company�� the United States-flagged fleet is engaged primarily in transporting refined products between the Gulf Coast and the East Coast and from California refineries to terminals on the West Coast and in Alaska and Hawaii. The foreign-flagged vessels are engaged primarily in transporting crude oil from the Middle East, Southeast Asia, the Black Sea, South America, Mexico and West Africa to ports in the United States, Europe, Australia and Asia. The Company�� foreign-flagged vessels also transport refined products to and from various locations worldwide.
Other Businesses
During 2012, the Company completed the sale of its Kemmerer, Wyoming, surface coal mine and the sale of its 50% interest in Youngs Creek Mining Company, LLC, which was formed to develop a coal mine in northern Wyoming.Chevron also owns and operates the Questa molybdenum mine in New Mexico. During 2012, it had 160 million tons of proven and probable coal reserves in the United States, including reserves of low-sulfur coal. The Company�� Global Power Company manages interests in 11 power assets with a total operating capacity of more than 2,200 megawatts, primarily through joint ventures in the United States and Asia. Chevron Energy Solutions (CES) completed several public sector programs, including a microgrid at the Santa Rita jail in Alameda County, and renewable and e! fficiency! programs for Huntington Beach City School District, South San Francisco Unified School District and Union City, all in California, plus Rootstown Local School District in Ohio. The Company�� energy technology organization supports Chevron�� upstream and downstream businesses by providing technology, services and competency development in earth sciences; reservoir and production engineering; drilling and completions; facilities engineering; manufacturing; process technology; catalysis; technical computing, and health, environment and safety disciplines.
Advisors' Opinion:- [By Chris Ciovacco]
The Energy Select Sector Spider provides exposure to a diversified basket of energy stocks, including Exxon (XOM), Chevron (CHV) and ConocoPhillips (COP). As the chart shows below, XLE has established a bullish weekly trend relative to the broader S&P 500 Index (SPY).
5 Best Oil Service Stocks To Buy For 2014: SouFun Holdings Ltd (SFUN)
SouFun Holdings Limited (SouFun), incorporated on June 17, 2004, operates as a real estate Internet portal in China. The Company also operates home furnishing and improvement Websites. Through SouFun's Websites, it provides marketing, e-commerce, listing, and other value-added services for China's real estate and home-related sectors. SouFun's Internet portal focuses and supports SouFun's users in seeking information on the real estate and home-related sectors in China. SouFun maintains about 100 offices to focus on local market needs and its Website and database contains real estate related content covering more than 320 cities in China. Its www.soufun.com Website contains links to other specialized real estate and home furnishing and improvement Websites, including its www.jiatx.com Website, its e-commerce transaction and payment platform. The Company's service offerings include marketing services, E-commerce services, listing services and other value-added services.
Marketing Services
The Company offers marketing services on its Websites, mainly through advertisements, to real estate developers in the marketing phase of new property developments, as well as to real estate agencies and suppliers of home furnishing and improvement and other home-related products and services who wish to promote their products and services. Its marketing services are delivered through its Website www.soufun.com and include traditional Internet advertisements, such as banners, links, logos and floating signs, as well as featured promotions, such as Internet advertisements, combined with its other services.
E-commerce services
The Company offers e-commerce services, including SouFun membership services and online transaction platform services. It provides both free and paid SouFun membership services to registered members its SouFun cards. Its free services include primarily regular updates regarding local property developments, tours to visit property developments an! d other services relating to property purchases. The Company�� paid services primarily include offers to purchase properties with discounts from its partner developers and information and related services to facilitate property purchases. In addition, through its www.jiatx.com Website, it offers an online transaction platform and related e-commerce services to home furnishing and improvement vendors in China.
Listing services
The Company offers basic and special listing services. Its basic listing services are mainly offered to real estate agents, brokers, developers, property owners and managers and suppliers of home furnishing and improvement and other home-related products and services. Its basic listing services allow its customers to post information of their products and services on its Websites. The Company�� special listing services offer customized marketing programs involving both online listings and offline themed events.
Other value-added services
The Company offers subscription-based access to its information database and research reports and total Web solution services. The Company provides online content subscription services on either a flat-fee subscription basis for database access or a per-project basis for its research services. It charge subscription fees based on the number of databases that the subscriber would like to access.
The Company competes with E-House (China) Holdings, Sohu.com Inc.�� focus.cn, Anjuke.com, Tencent�� fangqq.com, Szhome.com and House365.com.
Advisors' Opinion:- [By Selena Maranjian]
For example, consider Lone Pine Capital, founded by Steve Mandel�in 1997. Lone Pine is one of the biggest hedge fund companies, and it has reportedly outperformed�the S&P 500 handily since inception. Its reportable stock portfolio totaled $23 billion�in value as of March 31, 2014. According to its recently released 13F statement, Lone Pine established or added to positions in Jazz Pharmaceuticals plc (NASDAQ: JAZZ ) , SouFun Holdings Ltd (NYSE: SFUN ) , and Valeant Pharmaceuticals International (NYSE: VRX ) .
- [By Belinda Cao]
SouFun Holdings Ltd. (SFUN), China�� biggest real estate website, fell 2.8 percent to $23.01 April 5, extending its drop in the week to 12 percent. Short seller Glaucus Research Group rated the company a ��trong sell��in an April 4 report, saying that SouFun spent millions of dollars buying luxury real estate in New York and transferred money to charities of ��ubious authenticity.��
5 Best Oil Service Stocks To Buy For 2014: Novartis AG (NVS)
Novartis AG, incorporated on February 29, 1996, provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. Its portfolio includes medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. The Company has five segments: Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals; vaccines and diagnostics, which include human vaccines and blood-testing diagnostics, and consumer health, which include over-the-counter medicines (OTC) and Animal Health. On April 8, 2011, the Company acquired the remaining non-controlling interest in Alcon, Inc. In December 2013, Alliance Pharma plc announced that its wholly owned subsidiary, Alliance Pharmaceuticals Limited, acquired all the United Kingdom and Republic of Ireland (ROI) rights to Lypsyl from Novartis AG.
In April 2011, Novartis sells global rights to Elidel, a medicine to treat atopic dermatitis to Meda. In March 2011, Novartis completes acquisition of majority stake in Zhejiang Tianyuan vaccines company in China. In March 2011, the Company acquired Genoptix, Inc. In October 2011, Novartis discontinues development of AGO178 for depressive disorder. In December 2011, the Company discontinues development of PRT128 for acute coronary syndrome and chronic coronary heart disease, and SMC021 for osteoporosis and osteoarthritis. In April 2011, Alcon's portfolio of generic ophthalmic medicines sold through its Falcon business unit primarily in the United States.
Pharmaceuticals Division
The Company�� Pharmaceuticals Division researches, develops, manufactures, distributes and sells patented prescription medicines in the therapeutic areas, such as Oncol! ogy; Primary Care, consisting of Primary Care medicines and Established Medicines, and Specialty Care, consisting of Ophthalmology, Neuroscience, Integrated Hospital Care, and Critical Care medicines. The Pharmaceuticals Division is organized into global business franchises responsible for the commercialization of various products, as well as Novartis Oncology, a business unit responsible for the global development and commercialization of oncology products, and Novartis Molecular Diagnostics, a business responsible for the development and commercialization of diagnostic tests and services related to its pharmaceuticals portfolio and therapeutic areas.
The Company�� Oncology products include Afinitor/Votubia, Exjade, Sandostatin SC/Sandostatin LAR , Femara , Zometa, Tasigna and Gleevec/Glivec. Gleevec/Glivec, which is a signal transduction inhibitor approved to treat patients with certain forms of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Tasigna is a signal transduction inhibitor of the tyrosine kinase activity of Bcr-Abl, KIT+ and the PDGF-receptor. Zometa is a treatment to reduce or delay skeletal-related events (SREs), including pathologic fracture, spinal cord compression, and/or requirement of radiation therapy or surgery to bone, in patients with bone metastases (cancer that has spread to the bones) from solid tumors and multiple myeloma. Femara is a once-daily oral aromatase inhibitor for the treatment of early stage or advanced breast cancer in postmenopausal women. Sandostatin SC/Sandostatin LAR is indicated for the treatment of patients with acromegaly, a chronic disease caused by over-secretion of pituitary growth hormone in adults. Sandostatin is also indicated for the treatment of patients with certain symptoms associated with carcinoid tumors and other types of gastrointestinal and pancreatic neuroendocrine tumors. Exjade is an oral iron chelator approved for the treatment of chronic iron overload due to blood transfusions in patients over ! two years! of age who have a range of underlying anemias. Patients with congenital and acquired chronic anemia, such as thalassemia, sickle cell disease and myelodysplastic syndromes, require transfusions, which puts them at risk of iron overload. Afinitor/Votubia is an oral inhibitor of the mTOR pathway.
The Company�� Primary Care products include Arcapta Neohaler/Onbrez Breezhaler, Diovan, Exforge, Tekturna/Rasilez, Galvus, Reclast/Aclasta, Voltaren/Cataflam, Ritalin, Ritalin LA, Focalin and Focalin XR. Its Specialty Care products include Lucentis, Gilenya, Exelon, Extavia and Comtan, and Stalevo. Its Integrated Hospital Care include Zortress/Certican, Ilaris, Neoral and Myfortic.The Company�� Critical Care products include Xolair and Tobi Podhaler. As of December 31, 2011, the products under development includes ACZ885, which is being investigated for the secondary prevention of cardiovascular events and for the treatment of Diabetes Mellitus; AEB071 (sotrastaurin) is a low molecular weight, selective inhibitor of protein kinase-C (PKC); AFQ056 (mavoglurant) is a metabotropic glutamate receptor 5 (mGluR5) antagonist in Phase II development for the treatment of Parkinson's disease levodopa-induced dyskinesia; AIN457 (secukinumab) is a human monoclonal antibody neutralizing interleukin-17A, a key pro-inflammatory cytokine expressed by TH17 cells and other types of white blood cells; BAF312 is an oral, second-generation sphingosine 1-phosphate receptor modulator in Phase II development for relapsing-remitting multiple sclerosis; DEB025 (alisporivir) is a cyclophilin inhibitor for the treatment of Hepatitis C virus infection (HCV); Gileny a line treatment for relapsing forms of MS; Exjade (deferasirox) is an oral iron chelator in development for use in patients with non-transfusion-dependent thalassemia (NTDT); INC424 (ruxolitinib) is an investigational Janus kinase (JAK) inhibitor, and Zortress/Certican (everolimus) is an mTOR inhibitor with immune/non-immune cell proliferation inhibition being d! eveloped ! for prevention of solid organ transplant rejection.
Alcon Division
The Company�� Alcon Division discovers, develops, manufactures, distributes and sells eye care products. Alcon is engaged in eye care with product offerings in Surgical, Ophthalmic Pharmaceuticals and Vision Care. In Surgical, Alcon develops, manufactures, distributes and sells ophthalmic surgical equipment, instruments, disposable products and intraocular lenses. In Pharmaceutical, Alcon discovers, develops, manufactures, distributes and sells medicines to treat chronic and acute diseases of the eye, as well as over-the-counter medicines for the eye. In Vision Care, Alcon develops, manufactures, distributes and sells contact lenses and lens care products.
Alcon's Surgical portfolio includes the Infiniti vision system for cataract procedures, the Constellation vision system for retinal operations, and the AcrySof family of intraocular lenses (IOLs), including the AcrySof IQ, AcrySof IQ ReSTOR, AcrySof IQ Toric and AcrySof IQ ReSTOR Toric IOLs. During the year ended December 31, 2011, its Alcon Division launched the LenSx femtosecond laser, a technology in cataract surgery, which increases the precision and reproductibility for corneal incisions, capsulorhexis and lens fragmentation steps of the procedure. In addition, Alcon provides advanced viscoelastics, surgical solutions, surgical packs and other disposable products for cataract and vitreoretinal surgery.
Alcon Division's Ophthalmic Pharmaceuticals business combines Alcon's range of pharmaceuticals with selected ophthalmic products (excluding Lucentis) previously marketed by the Novartis Pharmaceuticals Division. The products treat chronic and acute diseases of the eye including glaucoma and allergies, as well as anti-infective/anti-inflammatory and dry eye treatments. our Alcon Division's Ophthalmic Pharmaceuticals portfolio include Travatan Z solution and DuoTrav solution for the treatment of elevated intraocular pressure associ! ated with! glaucoma; Vigamox solution for bacterial conjunctivitis; Pataday solution for ocular itching associated with allergic conjunctivitis; and Nevanac suspension for eye inflammation following cataract surgery. Alcon launched a number of products during 2011, including Dailies Total 1 lenses, Opti-Free EverMoist Multi Purpose Disinfecting Solution, LenSx laser, AcrySof IQ ReSTOR Toric lens, AcrySof IQ Toric T6-T9 lens, Travatan BAK-free solution, DuoTrav BAK-free solution, Moxeza solution and Systane Balance eye drops.
Sandoz Division
The Company�� Sandoz Division is a global generic pharmaceuticals company that develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical and biotechnological active substances, which are not protected by valid and enforceable third-party patents. The Sandoz Division has activities in Retail Generics, Anti-Infectives, and Biopharmaceuticals and Oncology Injectables. In Retail Generics, Sandoz develops, manufactures and markets active ingredients and finished dosage forms of pharmaceuticals, as well as supplying active ingredients to third parties. In Anti-Infectives, Sandoz develops and manufactures active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by retail generics and for sale to third-party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein- or other biotechnology-based products (biosimilars or follow-on biologics) and sells biotech manufacturing services to other companies.
In Oncology Injectables, Sandoz develops, manufactures and markets primarily cytotoxic products for the hospital market. During 2011, the Company launched generic docetaxel (Taxotere), higher-strength generic amlodipine-benazepril (Lotrel), generic meropenem (Merem) injection, and the formation of a women's health portfolio with generic Seasonale, Nordette, Yaz and Yasmin. The product launched in various European countries included generic docetaxel, ge! neric ana! strazole (Arimidex), and valsartan/covalsartan (an early entry generic version of Novartis Pharmaceuticals' Diovan/Co-Diovan).
Vaccines and Diagnostics Division
The Company�� Vaccines and Diagnostics Division researches, develops, manufactures, distributes and sells preventive vaccines and diagnostic tools. Novartis Vaccines is a global developer and manufacturer of human vaccines. Novartis Diagnostics is a blood testing and molecular diagnostics business dedicated to preventing the spread of infectious diseases through blood-screening tools that protect the world's blood supply. Novartis Vaccines' products include influenza, meningococcal, pediatric, adult and travel vaccines.
The Company�� influenza vaccines include Agrippal, Fluad, Fluvirin and Optaflu. Its Meningococcal Vaccines includes Menjugate and Menveo. Its travel vaccines include Encepur Children, Encepur Adults, Ixiaro and Rabipur/Rabavert. Its Pediatric Vaccines include Polioral and Quinvaxem.
Consumer Health
Consumer Health consists of two Divisions: OTC (over-the-counter medicines) and Animal Health. Each has its own research, development, manufacturing, distribution and selling capabilities. OTC offers readily available consumer medicine. Animal Health provides veterinary products for farm and companion animals.
OTC (over-the-counter medicines) offers products for the treatment and prevention of common medical conditions and ailments. OTC business focuses on a group of global brands in product categories that include treatments for cough/cold/respiratory (Triaminic, Otrivin, TheraFlu/NeoCitran), pain relief (Excedrin, Voltaren), digestive health (Benefiber, Prevacid24HR, Pantoloc Control), dermatology (Lamisil, Fenistil), and smoking cessation (Habitrol/Nicotinell).
Animal Health offers products and services focusing on both companion and farm animals (including cultivated fish). Key products for companion animals include Atopica (atopic dermatitis manageme! nt), Dera! maxx and Onsior (pain relief), Fortekor (heart failure in dogs, chronic renal insufficiency in cats), and Sentinel/Milbemax/Interceptor (intestinal parasite control and heartworm prevention), while farm animal products include the therapeutic anti-infective Denagard, an antimicrobial used to treat and control bacteria in swine, CLiK, an insect growth regulator used to control blowfly strike in sheep, cattle vaccines used to prevent respiratory and reproductive diseases in beef and dairy cattle, and Zolvix, a sheep drench representing the new sheep anthelmintic class. Aquaculture products include vaccines and treatments mainly used in salmon farming.
Advisors' Opinion:- [By James Well]
Pfizer (PFE) is one of the biopharmaceutical companies hardest hit by drugs losing patent exclusivity. Other big pharmaceutical companies affected by loss of patent protection include Merck (MRK), Johnson & Johnson (JNJ), Novartis (NVS) and Sanofi (SNY). Apart from battling with the loss of revenue due to loss of marketing exclusivity of their drugs, these companies are also packing drug pipelines to offset imminent patent expirations.
5 Best Oil Service Stocks To Buy For 2014: Cadence Design Systems Inc (CDS)
Cadence Design Systems, Inc. (Cadence) develops electronic design automation (EDA), software, hardware, and silicon intellectual property (IP). Cadence licenses software and IP, sells or leases hardware technology and provides engineering and education services worldwide to help manage and accelerate electronics product development processes. The Company�� customers use its products and services to design and develop complex integrated circuits (ICs) and electronics systems. The Company combines its products and technologies into platforms for four design activities: Functional Verification; Digital IC Design and Implementation; Custom IC Design and Verification, and System Interconnect Design. It sells software using three license types: subscription, term and perpetual. It also offers a number of fee-based services, including engineering and education services. In June 2010, Cadence acquired Denali Software, Inc. (Denali). In May 2011, it acquired Altos Design Automation, Inc. On July 11, 2011, the Company acquired Azuro, Inc. In July 2012, the Company acquired Sigrity, Inc. In April 2013, Cadence Design Systems Inc announced the acquisition of Tensilica, Inc. In May 2013, the Company acquired Cosmic Circuits Pvt Ltd. In June 2013, Cadence Design Systems Inc announced that it has completed the acquisition of the IP business of Poland-based Evatronix, SA SKA. In February 2014, Cadence Design Systems Inc completed the acquisition of Forte Design Systems.
The four Cadence design platforms are branded as Incisive functional verification, Encounter digital IC design, Virtuoso custom design and Allegro system interconnect design. In addition, the Company augments these platform product offerings with a set of design for manufacturing (DFM), products that service both the digital and custom IC design flows. These solutions and their constituent elements are marketed to users who specialize in areas, such as system design and verification, functional verification, logic design, digital imple! mentation, custom IC design and printed circuit board (PCB), and IC package / SiP design.
Functional Verification
Cadence�� functional verification offerings consist of two categories: Logic Verification and System Design and Verification. Logic Verification offering consists of planning, property checking, testbench simulation, verification IP, and environment capabilities within the Incisive functional verification platform. This offering enables the Company�� customers to employ enterprise-level verification process automation, including metric-driven verification planning, process tracking and management. System Design and Verification offerings consist of hardware-assisted verification with emulation and acceleration, including the verification computing platform Palladium XP, Palladium and Xtreme platforms, system-level design capabilities, verification IP, estimation of system-on-chip (SoC), consulting services, and methodologies. The QuickCycles program allows customers access to its simulation acceleration and emulation products, either on their secure Internet site or remotely over a secure network connection. The products obtained through the acquisition of Denali include verification IP, memory models, and design IP.
Digital IC Design and Implementation
Cadence�� Digital IC offerings are used by its customers to create logical representations of a digital circuit or IC. The Company�� Digital IC offerings include two categories: Logic Design and Physical Implementation. Logic Design offering consists of formal verification, equivalency checking, synthesis and test capabilities within the Encounter digital IC design platform and property checking, simulation, and environment capabilities within the Incisive functional verification platform. This offering provides chip planning, design, verification and test technologies and services to customers across all digital design end markets. Physical Implementation offering consists of a ra! nge of th! e Encounter digital IC design platform capabilities. The Physical Implementation offering includes timing analysis, signal integrity, power analysis, extraction, physical verification, and place and route capabilities within the Encounter digital IC design platform. It enables the customers to create a physical representation of logic models, analyze electrical and physical characteristics of a design and prepare a design for manufacturing.
Custom IC Design and Verification
Cadence�� Custom IC Design and Verification offerings are used by its customers to create schematic representations of circuits down to the transistor level for analog, mixed-signal, custom digital, memory and radio frequency (RF) designs. These logical representations are verified using simulation tools optimized for each type of design. The offering includes the environment, IC layout and simulation capabilities within the Virtuoso custom design platform. Other tools in the Custom IC portfolio are used to prepare the designs for manufacturing.
System Interconnect Design
Cadence�� System Interconnect Design offerings are used by its customers to develop printed circuit board (PCBs), and IC packages. The offerings include the capabilities within the Allegro system interconnect design platform: PCB, IC package, SiP, design management and collaboration. The Company�� offerings also include the simulation capability within the Virtuoso custom design platform. These offerings enable engineers who are responsible for the capture, layout and analysis of advanced PCB and IC packages to design electronic products across the domains of IC, IC package and PCB. For PCB customers, the Company provides the OrCAD family of offerings that is marketed worldwide through a network of resellers.
The Company competes with Synopsys, Inc., Mentor Graphics Corporation and Magma Design Automation, Inc.
Advisors' Opinion:- [By cody56]
The top contributors to performance during the period were Trimble Navigation (TRMB), Sensata Technologies�(ST) and Cadence Design Systems (CDS).
Trimble Navigation provides location-based solutions to its customers that enhance their productivity and profitability. The recovery in construction end markets and continued strong demand from the farm economy resulted in strong overall financial results for the company and a strong stock price. We trimmed the position as it began to exceed the upper end of the market cap range that we invest in. Sensata Technologies develops, manufactures and sells sensors and controls. We are attracted to the company�� large growth opportunity, which is driven by increased sensor penetration in industries such as automobiles and general industrial opportunities. We find Sensata�� business model to be attractive given the stability of its revenues, strong operating leverage and excellent management team. During the period, the company benefited from a rebound in European automobile sales and deployed capital in several small accretive acquisitions. We have been trimming the position modestly as the stock approaches our price target.Meridian Growth Fund performance
- [By Jim Jubak]
The price of Credit-Default Swaps (CDS) used to insure US government debt against the possibility of default climbed to 35.5 basis points Wednesday. That was the highest level in six months, and up from 32 basis points on Friday, September 27. But that level is still well below the 62 basis points it cost to insure US government debt against default at the time of last debt ceiling battle, in the summer of 2011. That was the highest level since the global financial crisis. (What this means is that an investor would pay 62,000 euros a year to insure 10 million euros of US Treasuries against a default in the next five years. The contract is denominated in euros to offset the impact of a default on the US dollar.) This insurance is getting more popular too, with these CDS contracts ranking as the fifteenth most traded of the contracts tracked by the Depository Trust & Clearing Corp. in the week through Sept. 27. That's up from a rank of 147th for the previous week.
No comments:
Post a Comment